8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T16996 | TAS6417 | Apoptosis , EGFR | |
TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM). | |||
T2490 | Osimertinib | AZD-9291,Mereletinib | EGFR |
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activi... | |||
T3634 | Osimertinib mesylate | Mereletinib mesylate,AZD-9291 mesylate | EGFR |
Osimertinib mesylate (Mereletinib mesylate) is an irreversible and mutant selective EGFR inhibitor (IC50s: 12/1 nM for EGFR(L858R) and EGFR(L858R/T790M)). | |||
T15044 | D609 | Apoptosis , Antioxidant | |
D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective acti... | |||
T61935 | B-Raf IN 9 | ||
B-Raf IN 9 (compound 8b) is an effective B-Raf inhibitor (IC50=24.79 nM). B-Raf IN 9 blocks cell cycle at G2/M phase and induces apoptosis. B-Raf IN 9 showed potent anti-tumor activity on human prostate cancer PC-3 cells... | |||
T79152 | PROTAC EGFR degrader 8 | EGFR | |
PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells. It effectively inhibits the growth of various cell lines, includin... | |||
T37585 | Ensartinib | ||
Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or ... | |||
T35897 | ASK120067 | ||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]... |